Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

Bristol-Myers Squibb and Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

Source: 
CP Wire
snippet: 
  • Factor XIa inhibitor moving into Phase 2 Trials for Secondary Stroke Prevention
  • Factor Xia was first noticed as a potential approach to thrombosis because people with little or no FXIa (Hemophilia C) show virtually no untoward bleeding in the absence of a major injury or surgery